Retina Foundation Of The Southwest

Opus Genetics Gene Therapy Shows Promise in Restoring Vision for Inherited Blindness

- Opus Genetics' investigational gene therapy OPGx-LCA5 is helping individuals born blind regain partial sight in an ongoing Phase 1/2 clinical trial. - The therapy targets mutations in the LCA5 gene by delivering a functional copy directly to retinal cells to restore photoreceptor function. - Patient Lindsey Rambo, the second participant in the trial, shared her experience on Good Morning America, highlighting the life-changing potential of the treatment. - The company is advancing multiple gene therapy programs for inherited retinal diseases, including trials for both LCA5 and BEST1 mutations.